<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40"><head><meta http-equiv=Content-Type content="text/html; charset=us-ascii"><meta name=Generator content="Microsoft Word 15 (filtered medium)"><!--[if !mso]><style>v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style><![endif]--><style><!--
/* Font Definitions */
@font-face
{font-family:Helvetica;
panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:New;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0cm;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
h1
{mso-style-priority:9;
mso-style-link:"Heading 1 Char";
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:24.0pt;
font-family:"Calibri",sans-serif;
font-weight:bold;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
span.Heading1Char
{mso-style-name:"Heading 1 Char";
mso-style-priority:9;
mso-style-link:"Heading 1";
font-family:"Calibri",sans-serif;
font-weight:bold;}
p.ydp2db168f9yiv7878028198msonormal, li.ydp2db168f9yiv7878028198msonormal, div.ydp2db168f9yiv7878028198msonormal
{mso-style-name:ydp2db168f9yiv7878028198msonormal;
mso-style-priority:99;
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
span.EmailStyle23
{mso-style-type:personal-reply;
font-family:"Calibri",sans-serif;
color:windowtext;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:612.0pt 792.0pt;
margin:72.0pt 72.0pt 72.0pt 72.0pt;}
div.WordSection1
{page:WordSection1;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]--></head><body lang=EN-CA link="#0563C1" vlink="#954F72" style='word-wrap:break-word'><div class=WordSection1><p class=MsoNormal><span style='mso-fareast-language:EN-US'>Hi all:<o:p></o:p></span></p><p class=MsoNormal><span style='mso-fareast-language:EN-US'>See note below.<o:p></o:p></span></p><p class=MsoNormal><span style='mso-fareast-language:EN-US'>Take care & stay well.<o:p></o:p></span></p><p class=MsoNormal><span style='mso-fareast-language:EN-US'><o:p> </o:p></span></p><p class=MsoNormal><span style='mso-fareast-language:EN-US'>Glen<o:p></o:p></span></p><p class=MsoNormal><span style='mso-fareast-language:EN-US'><o:p> </o:p></span></p><div><div style='border:none;border-top:solid #E1E1E1 1.0pt;padding:3.0pt 0cm 0cm 0cm'><p class=MsoNormal><b><span lang=EN-US>From:</span></b><span lang=EN-US> Gary Foote - PCCN Brampton <br><b>Sent:</b> May 5, 2021 10:23 AM<br><b>To:</b> visact@rogers.com<br><b>Subject:</b> Avodart Class Action Settlement<o:p></o:p></span></p></div></div><p class=MsoNormal><o:p> </o:p></p><h1 style='mso-margin-top-alt:5.0pt;margin-right:0cm;margin-bottom:7.5pt;margin-left:36.0pt'><span lang=EN-US style='font-size:27.0pt;font-family:"Arial",sans-serif;color:#333333;text-transform:uppercase'>AVODART CANADA-WIDE SETTLEMENT</span><span lang=EN-US style='font-family:"Helvetica",sans-serif;color:#26282A'><o:p></o:p></span></h1><p style='mso-margin-top-alt:5.0pt;margin-right:0cm;margin-bottom:7.5pt;margin-left:36.0pt;background:white'><strong><span lang=EN-US style='font-size:10.5pt;font-family:"Arial",sans-serif;color:gray'>April 30, 2021</span></strong><span lang=EN-US style='font-size:10.5pt;font-family:"Arial",sans-serif;color:gray'> — A former class action regarding Avodart has been discontinued and abandoned against the drug manufacturer (GlaxoSmithKline) regarding allegations that using Avodart can cause high grade prostate cancer, and permanent or temporary sexual dysfunction. These allegations were not proven in Court. The Avodart class action has been fully discontinued.</span><span lang=EN-US style='font-size:10.0pt;font-family:"Helvetica",sans-serif;color:#26282A'><o:p></o:p></span></p><p style='mso-margin-top-alt:5.0pt;margin-right:0cm;margin-bottom:7.5pt;margin-left:36.0pt;background:white'><span lang=EN-US style='font-size:10.5pt;font-family:"Arial",sans-serif;color:gray'> </span><span lang=EN-US style='font-size:10.0pt;font-family:"Helvetica",sans-serif;color:#26282A'><o:p></o:p></span></p><p style='mso-margin-top-alt:5.0pt;margin-right:0cm;margin-bottom:7.5pt;margin-left:36.0pt;background:white'><span lang=EN-US style='font-size:10.5pt;font-family:"Arial",sans-serif;color:gray'>However, GlaxoSmithKline has agreed to settle (on an individual basis) certain qualifying legal claims made by Canadian residents who (1) have used Avodart and (2) were subsequently diagnosed with <u>high grade prostate cancer</u>.</span><span lang=EN-US style='font-size:10.0pt;font-family:"Helvetica",sans-serif;color:#26282A'><o:p></o:p></span></p><p style='mso-margin-top-alt:5.0pt;margin-right:0cm;margin-bottom:7.5pt;margin-left:36.0pt;background:white'><span lang=EN-US style='font-size:10.5pt;font-family:"Arial",sans-serif;color:gray'>The same individual compensation process is currently underway and the deadline to apply for individual compensation is July 28, 2021. No individual claims can be submitted after July 28, 2021. If you have been diagnosed with <u>high grade prostate cancer and previously used Avodart, please contact our law firm ASAP.</u></span><span lang=EN-US style='font-size:10.0pt;font-family:"Helvetica",sans-serif;color:#26282A'><o:p></o:p></span></p><p style='mso-margin-top-alt:5.0pt;margin-right:0cm;margin-bottom:7.5pt;margin-left:36.0pt;background:white'><span lang=EN-US style='font-size:10.5pt;font-family:"Arial",sans-serif;color:gray'> </span><span lang=EN-US style='font-size:10.0pt;font-family:"Helvetica",sans-serif;color:#26282A'><o:p></o:p></span></p><p style='mso-margin-top-alt:5.0pt;margin-right:0cm;margin-bottom:7.5pt;margin-left:36.0pt;background:white'><span lang=EN-US style='font-size:10.5pt;font-family:"Arial",sans-serif;color:gray'>For more information, you should immediately email our law firm at: <a href="mailto:Avodart@merchantlaw.com" target="_blank"><span style='color:#428BCA'>Avodart@merchantlaw.com</span></a> with details regarding your high grade prostate cancer and Avodart usage. Please also provide your full contact information. [You may also call our law office for a free initial consultation without obligation, at </span><span lang=EN-US style='font-size:10.5pt;font-family:"Arial",sans-serif;color:#428BCA'>306-653-7756</span><span lang=EN-US style='font-size:10.5pt;font-family:"Arial",sans-serif;color:gray'>, regarding Avodart compensation claims from anywhere in Canada.]</span><span lang=EN-US style='font-size:10.0pt;font-family:"Helvetica",sans-serif;color:#26282A'><o:p></o:p></span></p><p style='mso-margin-top-alt:5.0pt;margin-right:0cm;margin-bottom:7.5pt;margin-left:36.0pt;background:white'><span lang=EN-US style='font-size:10.5pt;font-family:"Arial",sans-serif;color:gray'>Please take note of the following court-approved documentation [in PDF below] regarding this settlement:</span><span lang=EN-US style='font-size:10.0pt;font-family:"Helvetica",sans-serif;color:#26282A'><o:p></o:p></span></p><p class=ydp2db168f9yiv7878028198msonormal style='margin-left:72.0pt;background:white'><span lang=EN-US style='font-size:10.0pt;font-family:Symbol;color:gray'>·</span><span lang=EN-US style='font-size:7.0pt;font-family:New;color:gray'> </span><span lang=EN-US style='font-size:10.5pt;font-family:"Arial",sans-serif;color:gray'>The <a href="https://www.merchantlaw.com/wp-content/uploads/2021/04/Exhibit-1-Quebec-Notice-of-discontinuance-revised-french-and-english.pdf" target="_blank"><span style='color:#428BCA'>public notice</span></a> issued by the Quebec Superior Court and underlying <a href="https://www.merchantlaw.com/wp-content/uploads/2021/04/jugement-desistement.pdf" target="_blank"><span style='color:#428BCA'>Judgment</span></a></span><span lang=EN-US style='font-size:10.0pt;font-family:"Helvetica",sans-serif;color:#26282A'><o:p></o:p></span></p><p class=ydp2db168f9yiv7878028198msonormal style='margin-left:72.0pt;background:white'><span lang=EN-US style='font-size:10.0pt;font-family:Symbol;color:gray'>·</span><span lang=EN-US style='font-size:7.0pt;font-family:New;color:gray'> </span><span lang=EN-US style='font-size:10.5pt;font-family:"Arial",sans-serif;color:gray'>The <a href="https://www.merchantlaw.com/wp-content/uploads/2021/04/Ontario-Notice.pdf" target="_blank"><span style='color:#428BCA'>public notice</span></a> issued by the Ontario Superior Court</span><span lang=EN-US style='font-size:10.0pt;font-family:"Helvetica",sans-serif;color:#26282A'><o:p></o:p></span></p><p class=ydp2db168f9yiv7878028198msonormal style='margin-left:36.0pt'><span lang=EN-US style='font-size:10.0pt;font-family:"Helvetica",sans-serif;color:#26282A'> <o:p></o:p></span></p><p class=ydp2db168f9yiv7878028198msonormal><span lang=EN-US style='font-size:10.0pt;font-family:"Helvetica",sans-serif;color:#26282A'>Thanks all,<o:p></o:p></span></p><p class=ydp2db168f9yiv7878028198msonormal><span lang=EN-US style='font-size:10.0pt;font-family:"Helvetica",sans-serif;color:#26282A'> <o:p></o:p></span></p><p class=ydp2db168f9yiv7878028198msonormal><span lang=EN-US style='font-size:10.0pt;font-family:"Helvetica",sans-serif;color:#26282A'><img border=0 width=410 height=205 style='width:4.2708in;height:2.1354in' id="Picture_x0020_1" src="cid:image001.png@01D74198.9316D320"></span><span lang=EN-US style='font-size:10.0pt;font-family:"Helvetica",sans-serif;color:#26282A'><o:p></o:p></span></p><p class=ydp2db168f9yiv7878028198msonormal><span lang=EN-US style='font-size:9.0pt;font-family:"Helvetica",sans-serif;color:#26282A'>If you wish to join the Prostate Cancer Support mailing list to receive reminders for upcoming support group meetings and monthly newsletters, <a href="https://mailchi.mp/455c8826d5c1/support-group-mailing-list" target="_blank">please click here.</a> </span><span lang=EN-US style='font-size:10.0pt;font-family:"Helvetica",sans-serif;color:#26282A'><o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-size:12.0pt;font-family:"Arial",sans-serif'><o:p> </o:p></span></p></div></body></html>